How Kite, A Gilead Company, is Building a Global CAR T Franchise out of Los Angeles

Learn how Kite’s focus on cell therapy to treat cancer has advanced industry-leading pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) product candidates to treat both hematological cancers and solid tumors.
MODERATOR:
Antonio Bernardo, Dean and John E. Anderson Chair in Management, UCLA Anderson School of Management
KITE, a GILEAD COMPANY SPEAKERS:
Mert Aktar, Vice President and Head of Corporate Development
Matt Hostetler, Vice President and Head of Human Resources
Francesco Marincola, Global Head of Cell Therapy Research
Frank Neumann, Global Head of Clinical Development